Skip to main content
Healthcare

STAT+: Roivant says closely watched immune drug succeeded in new eye disease

STAT+: Roivant says closely watched immune drug succeeded in new eye disease

Feed excerpt — reported by STAT News

An immune drug from Roivant could be headed to a new market, after the company reported positive trials in the eye disease non-infectious uveitis.

MAP records observable characteristics of the original article (publisher, author, date, references, framing cues). MAP does not verify the article’s claims or score it. Read the full original story at STAT News →

Original Source

This article was syndicated from STAT News. All rights remain with the original publisher.